← Storyflo·storyflo · health and longevity· health
Health
Daily Health & Wellness Brief · September 3rd
storyflo · health and longevity
Sep 3, 2026 · 3 min listen · Last updated September 3, 2026
From storyflo. This is your daily audio brief. Chloe, September 3rd. Quick run through ten health stories — let's start with the longevity piece. Let's get into it. First, from jwby. 1, #199 - Amp it up. The article dives into the tension between wanting to push for bigger and faster results while also recognizing the need for balance.
Listen · storyflo · health and longevity
Daily Health & Wellness Brief · September 3rd
0:00-3:06
Pick your daily storyteller
Subscribe to match with Theo, Jessica, Chloe, Mason, Brock — your voice, every brief.
Daily Health & Wellness Brief · September 3rd · Storyflo
culture
Audio pre-rendered by Storyflo · cached + delivered from the edge
1, #199 - Amp it up
The article dives into the tension between wanting to push for bigger and faster results while also recognizing the need for balance. The author reflects on their own instinct to slow things down in a culture that often prioritizes speed and scale. They introduce the concept of "Amp it up," a guiding philosophy from a well-known CEO, which focuses on three main principles: raising standards, increasing tempo, and sharpening focus.
While these ideas might seem cliché, the real insight lies in how sharpening focus can help achieve higher quality and speed simultaneously. The author emphasizes that prioritizing ruthlessly is key; it’s about making tough choices to ensure that quality doesn’t get lost in the rush for speed. The article wraps up with a nod to the familiar saying: “Good, Fast, Cheap: Pick 2,” highlighting the trade-offs that come with striving for excellence.
From 2021 to 2023, the U.S. faced a staggering number of drug overdose deaths, exceeding 105,000 annually, which was already a significant rise compared to pre-pandemic levels. However, there’s been a notable shift: in 2024, overdose deaths in the U.S. dropped by 27%. Preliminary data for 2025 suggests this trend may continue, though the overall mortality rate remains concerningly high.
Interestingly, this decline isn’t limited to the U.S. Other countries grappling with overdose crises also reported reductions. Scotland experienced a 13% decrease in 2024, while Canada saw a 9% drop. It seems like a collective response might be taking shape, but the situation still requires careful attention.
Neurodivergent Burnout Isn't In Your Mind. It's In Your Cells.
Burnout is often seen as a mental struggle, especially for those who are high-achieving and conscientious. When they hit a wall, the advice usually revolves around self-care, setting boundaries, and therapy. But for many, these strategies don’t lead to recovery, leaving them feeling stuck and exhausted.
Recent discussions suggest that burnout might not just be a psychological issue; it could also be rooted in biological changes at the cellular level. This perspective challenges the traditional understanding of burnout and highlights the need for a more comprehensive approach. It’s about recognizing that the experience of burnout is complex and may require deeper exploration beyond typical self-care advice.
Today’s little moments remind us to appreciate the simple joys in life. First up, that satisfying feeling when your ear pops, especially when you’re on a plane or driving up a mountain. It’s such a small thing, but it can really brighten your day. Then, there’s the relief and gratitude that comes with a safe landing after a flight—it's a reminder of how far we've come and the journeys we take. Lastly, spending time in the mountains with dear friends can be incredibly grounding. It’s those connections and shared experiences that really enrich our lives. What are three good things for you today?
Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for
Ultragenyx recently announced that its Phase 3 trial for a new treatment targeting Angelman syndrome did not meet its goals. This therapy, which was designed to address the underlying genetic issues of the condition, aimed to improve symptoms in individuals with this rare neurodevelopmental disorder.
While the specifics of the trial results aren't fully detailed yet, this outcome is a significant disappointment for both the company and the families affected by Angelman syndrome. The search for effective treatments continues, but this setback highlights the challenges in developing therapies for complex genetic conditions.
Moving forward, Ultragenyx will likely analyze the data to understand what went wrong and consider next steps, but for now, this news serves as a reminder of the difficulties in advancing new treatments in the field of rare diseases.
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to storyflo · health and longevity.